I-Mab

I-Mab is a biotechnology company focused on developing immuno-oncology agents for cancer treatment in the United States. Its pipeline includes givastomig, a bispecific antibody in Phase 1b trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody in Phase 1 trials for solid tumors. The company has a strategic licensing agreement with Ferring International Center SA for FE301, an interleukin-6 inhibitor, and collaborations with Bristol Myers Squibb, ABL Bio, Inc., and TJ Bio. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.